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www.cdatm.orgAbstractObjective: To evaluate the maintenance effect of probiotics versus that of aminosalicylates on ulcerative colitis.
Methods: MEDLINE, EMBASE, the Cochrane Controlled Trials Register, and the Chinese Biomedical Database were searched in
English or Chinese. Data extracted were selected with strict criteria.
Results: In six randomized controlled trials (RCTs), a total of 721 participants were enrolled and the maintenance effect of
probiotics (n ¼ 364) versus that of aminosalicylates (n ¼ 357) on ulcerative colitis was investigated. No significant difference was
observed between probiotics and aminosalicylate groups (relative risk (RR) ¼ 1.08; 95% confidence interval (CI): 0.91e1.28;
P¼ 0.40). Three RCTs compared the incidence of adverse events with probiotics versus those with aminosalicylates. No significant
difference was observed in the incidence of adverse events between the two groups (RR ¼ 1.20; 95% CI: 0.92e1.56; P ¼ 0.17).
Conclusions: Probiotics and aminosalicylates both showed a maintenance effect on ulcerative colitis. However, more well-
designed RCTs are required.
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Ulcerative colitis (UC) is a relapsing, chronic,
immune-mediated intestinal disease that mainly affects
the large bowel, and whose causes and etiology remain
unknown. Its main symptoms are watery or bloody
stools, abdominal pain, urinary urgency and (or)
tenesmus.1 Consequently, UC severely affects patients'
quality of life.Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
ons.org/licenses/by-nc-nd/4.0/).
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nance treatment in patients with UC.2 However, many
patients are intolerant to either classic aminosalicylate
sulfasalazine or sulfur-free compounds. In addition, the
potential side effects, costs, and a poor compliance to
long-time therapy, have led researchers to look for
novel therapeutic approaches.3
Probiotics are live microbial feed supplements, which
beneficially affect the host by altering the enteric flora.
Increasing evidence indicates the role of intestinal micro
flora in the pathogenesis of UC.4e6 Although several
observations have suggested that some probiotics and
aminosalicylates have comparable effects in the mainte-
nance of remission in UC,3,7e17 the evidence is based on
a relatively few number of studies, which are not suffi-
cient to determine whether they are definitely helpful or
harmful. Therefore, the present meta-analysis systemat-
ically identifies and analyzes randomized controlled trials
(RCTs) in order to evaluate the maintenance effect
of probiotics versus that of aminosalicylates on UC.
Materials and methods
Search strategy
We searched for RCTs from the following data-
bases: MEDLINE (1966 to August 2015), EMBASE
(1980 to August 2015), the Cochrane Controlled Trials
Register (1995 to August 2015), and the Chinese
Biomedical Database (1981 to March 2015). The
keywords used were probiotic, Lactobacillus, Bifido-
bacterium, Saccharomyces, Escherichia coli, yeasts,
probiotic mixture VSL#3, mesalazine, osalazine, 5-
aminosalicylic acid (5-ASA), balsalazide, and ulcera-
tive colitis, maintenance of remission, or relapse. The
studies were limited to those published in English or
Chinese. Moreover, manual searching of reference
lists, authors, and associated meeting reports or ab-
stracts was also performed. Two participators (Yong
Jiang and Ying Zhang) searched the results.
Selection criteria and quality assessment
The selection criteria were as follows: (a) They were
RCTs; (b) Both adult and children studies were
included; (c)Meeting reports or abstracts were included;
(d) The studies compared the maintenance effect of
probiotics to aminosalicylates with standard therapy for
UC; (e) Patients who had UC used definite diagnostic
standards; (f) Reviews and case reports were excluded.
Two participants selected the articles after careful
searching. We evaluated the quality of each selectedarticle and verified the details. When discrepancies
occurred, a third author (Feng-Xiang Qi) resolved
them. The quality of the selected RCTs was assessed
by the Cochrane Reviewer Handbook 5.0, RCTs'
quality assessment standard, using the following
criteria: sequence generation, allocation sequence
concealment, blinding method, incomplete outcome
data, and selective outcome reporting.18 The Jadad
score was used to evaluate the quality of every RCT.
High-quality RCTs, which scored three points or more,
were included in this meta-analysis.19
Statistical analysis
The statistical analysis was performed using
Cochrane Collaboration's Revman 5.3 software.
Relative risks (RR) with 95% confidence interval (CI)
were calculated based on the studies. A statistical
heterogeneity test was performed by using the Chi-
square test and I2 statistics, and an I2 value of more
than 50% was considered to have substantial hetero-
geneity. A random-effects model was selected when
the heterogeneity test showed an I2 value of more
than 50%; otherwise, a fixed-effects model was
used.18 Subgroup analyses were used depending on
species of probiotic. A funnel plot was used as an
indicator of publication bias when the number of
studies was 5 or more.
Results
We identified 4984 relevant studies from the literature
searched. Nineteen potentially eligible stud-
ies3,7e17,20e26 were initially identified; however, two
studies7,13 were excluded as they studied the mainte-
nance effect of probiotics without aminosalicylates, four
studies14e17 were excluded as they were meta-analyses,
and seven studies20e26 were excluded as they only
observed the induction of remission of UC (Table 1).
Eventually, six RCTs3,8e12 (four in English and two in
Chinese) that satisfied the inclusion criteria were iden-
tified and included in the analyses (Fig. 1, Table 2).
Study characteristics
Six RCTs with a total of 721 participants were pub-
lished during 1999e2009. The length of follow-up of
these trials ranged from 3 to 12 months. Five stud-
ies3,8e10,12 were conducted on adults, and one study11 on
children. Each of the five adult studies scored 4 points
and the one pediatric study scored 3 points, respectively,
based on the quality assessment criteria (Table 3).
Table 1
Characteristics of excluded studies.
Authors Year Journal Reason for exclusion
Kruis et al7 1997 Aliment Pharmacol Ther Did not compare to aminosalicylates
Miele et al13 2009 Am J Gastroenterol Did not compare to aminosalicylates
Kato et al20 2004 Aliment Pharmacol Ther Only studied the induction of remission
Tursi et al21 2004 Med Sci Monit Only studied the induction of remission
Furrie et al22 2005 Gut Only studied the induction of remission
Sood et al23 2009 Clin Gastroenterol Hepatol Only studied the induction of remission
Matthes et al24 2010 BMC Complement Altern Med Only studied the induction of remission
Ng et al25 2010 Inflamm Bowel Dis Only studied the induction of remission
Tursi et al26 2010 Am J Gastroenterol Only studied the induction of remission
Sang et al14 2010 World J Gastroenterol Meta-analysis
Naidoo et al15 2011 Cochrane Database Syst Rev Meta-analysis
Shen et al16 2014 Inflamm Bowel Dis Meta-analysis
Fujiya et al17 2014 Clin J Gastroenterol Meta-analysis
Fig. 1. Flowchart of selecting process for meta-analysis.
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Six studies investigated the maintenance effect of
probiotics versus that of aminosalicylates on UC.
Bifidobacterium longum was used as the probioticTable 2
Characteristics of included studies.
Authors Year Country Probiotic Contro
group
Cui et al10 2007 China Bifidobacterium
longum
Mesala
Henker et al11 2008 Germany E. coli Nissle 1917 5-ASA
Kruis et al9 2004 Germany E. coli Nissle 1917 Mesala
Ma et al12 2009 China Lactobacillus GG Mesala
Rembacken et al8 1999 United Kingdom E. coli Nissle 1917 5-ASA
Zocco et al3 2006 Italy Lactobacillus GG Mesala
UC: ulcerative colitis; tid: three times a day; 5-ASA: 5-aminosalicylic acid;treatment in one study.10 E. coli Nissle 1917 was used
as the probiotic treatment in three studies.8,9,11 The
other two studies used Lactobacillus GG as the pro-
biotic treatment.3,12 Four studies3,9,10,12 used mesala-
zine as the control intervention, and the other twol Dose of
pro-biotic/day
Dose of
mesalazine
Degree of UC Treatment
duration
zine 6  107 500 mg tid Mild to moderate 3 months
5  1010 1500 mg/d Not mentioned 12 months
zine (2.5e25)  109 500 mg tid Not mentioned 12 months
zine Not mentioned 420 mg bid Not mentioned 12 months
5  1010 400 mg tid Not mentioned 12 months
zine 18  109 800 mg tid Not mentioned 12 months
d: day; bid: twice a day.
Table 3
Methodological quality of the six RCTs.
Authors Year Random
method
Allocation
concealment
Blind
method
Lost
or exit
Inclusion/
exclusion criteria
Jadad
score
Cui et al10 2007 High Unclear Unclear Unclear High 3
Henker et al11 2008 High High Unclear Unclear High 4
Kruis et al9 2004 High Unclear Unclear High High 4
Ma et al12 2009 High Unclear High High High 4
Rembacken et al8 1999 High High Unclear High High 4
Zocco et al3 2006 High Unclear Unclear High High 4
RCTs: randomized controlled trials.
37Y. Jiang et al. / Chronic Diseases and Translational Medicine 2 (2016) 34e41studies8,11 used 5-ASA as the control intervention. The
observation intervals were 12 months in the five adult
studies, and 3 months in the pediatric study. None of
the studies showed significant difference in the main-
tenance effect between the experimental groups and
control groups. The meta-analysis showed no signifi-
cant difference between the probiotics groups and
aminosalicylate groups (P ¼ 0.40). The relapse rate
was 40.4% (147/364) in the probiotics group,
compared to 38.7% (138/357) in the aminosalicylate
group. The pooled RR for the maintenance effect of
probiotics versus that of aminosalicylates on UC was
1.08, with a 95% CI of 0.91e1.28. No significant
difference was found in the heterogeneity of the total
recurrence rate (P ¼ 0.69, I2 ¼ 0%) (Fig. 2).
We divided pooled trials into three subgroups ac-
cording to different species of probiotics (Fig. 3). The
first subgroup compared the maintenance effect of E.
coli Nissle 1917 to that of 5-ASA/mesalazine on UC.
There was no significant difference in the maintenance
effect between the two groups (P ¼ 0.32) and theFig. 2. The forest plot of relapse rate of ppooled RR was 1.11, with a 95% CI of 0.91e1.35. The
second subgroup compared Lactobacillus GG to
mesalazine, which showed that there was no significant
difference between the two groups (P ¼ 0.67); the
pooled RR was 0.77, with a 95% CI of 0.36e1.65. The
third subgroup compared B. longum to mesalazine, and
found no significant difference between the two groups
(P ¼ 0.57); the pooled RR was 1.12, with a 95% CI of
0.76e1.64.
Adverse events
Three studies8,9,12 investigated the incidence of
adverse events between probiotics and amino-
salicylates. Meta-analysis of the trials showed no sig-
nificant difference between the interventions
(RR ¼ 1.20, 95% CI: 0.92e1.56, P ¼ 0.17) (Fig. 4).
Adverse events were reported in 33.2% (77/232) of
patients treated with probiotics and in 27.6% (66/239)
of patients treated with aminosalicylates. Adverse
events included symptoms such as bloody stools,robiotics group versus control group.
Fig. 3. The forest plot of relapse rate of diffident probiotic group versus control group (subgroup).
Fig. 4. The adverse events between probiotics and control group.
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events included headaches, nausea, or viral infections.
Qualitative evaluation of publication bias
An inverted funnel plot can analyze the results of a
fixed-effects model. Fig. 5 shows a symmetrical
inverted funnel plot, indicating that there was no
visible publication bias in the relative remission rates
between the probiotics group and control group.Fig. 5. Inverted funnel plot analysis of the relative of remission rate
between probiotics group and control group.Discussion
UC is a chronic relapsing disease that mainly affects
the large bowel, which can negatively affect patients'
quality of life. The ideal definition of relapse preven-
tion includes longer symptom-free intervals with fewer
adverse events. Standard maintenance therapy involves
a variety of treatments including aminosalicylates,
biological agents, and immunosuppressant therapy.
However, these treatments are expensive, and have
potential adverse events and high non-adherence rates,
and as such, alternative medications are required.
Probiotics are thought to have fewer adverse effects
than current medications and have been proposed as an
alternative treatment option. Recent evidence has
supported the potential therapeutic role of probiotics in
the treatment of UC. Several mechanisms have been
proposed, including inhibiting the growth of patho-
genic bacteria,27 reinforcing the function of intestinal
barriers,28 and protecting immune responses through
immunization.29 However, the clinical results of pro-
biotic treatments for UC are still unclear. Thus, more
research is required before probiotics can be accepted
as a standard medication for treating UC.
The results from this meta-analysis showed that
probiotics reduced the recurrence of UC and might beas effective as aminosalicylates. To study the effect of
different species of probiotics (E. coli Nissle 1917,
Lactobacillus GG, B. longum) on maintaining the
remission of UC, we divided the pooled trials into 3
subgroups. None of the studies showed significant
difference in the maintenance effect between experi-
mental groups and control groups. However, the
number of patients in the pooled analysis was rela-
tively small; therefore, it is difficult to conclude if
probiotics can have a meaningful impact in clinical
practice.
Persborn et al28 observed the effect of probiotics on
barrier function and mucosal pouch microbiota in cases
of UC, and found that probiotics restored the mucosal
barrier of E. coli and horseradish peroxidase in patients
with pouchitis, which may influence the prevention of
UC recurrence during maintenance treatment. Adam
et al30 showed that the maintenance effect of the pro-
biotic E. coli Nissle on UC was as effective as standard
mesalazine. Other studies found that E. coli Nissle can
prevent the intrusion of Salmonella typhimurium to the
intestinal tract, inhibit the intrusion of pathogenic
enterobacteria,31 and reduce intestinal flora constitu-
ents in patients with UC.32 Thus, there is evidence to
support the efficacy of E. coli in UC maintenance
treatment.
Kato et al20 found that supplementation with
bifidobacteria-fermented milk products is safe, and
more effective than conventional treatments alone in
patients with active UC. Cui et al33 also observed that
bifidobacteria can impede the activation of nuclear
factor-kB, decrease the expressions of tumor necrosis
factor-a and interleukin-1b, and elevate the expression
of interleukin-10 in patients with UC. These results
suggest that bifidobacteria are effective in preventing
flare-ups of chronic UC and may have potential in UC
maintenance treatment.
VSL#3, a mixture of eight different probiotic bac-
teria, has successfully been used in the clinic to treat
UC. Some in vitro studies have implicated that VSL#3
can suppress lipopolysaccharide-induced chemokine
production by inhibiting signal transducer and activator
of transcription 1 phosphorylation.34 Mariman et al35
studied C57BL/6 and BALB/c mice, and found that
VSL#3 mediated both pro- and anti-inflammatory re-
sponses in bone marrow-derived dendritic cells. Dai
et al36 demonstrated that VSL#3 exerted anti-
inflammatory activity via the phosphoinositide 3-
kinase/protein kinase B and nuclear factor-kB
pathway in a rat model of dextran sulfate sodium-
induced colitis. A meta-analysis37 of VSL#3 added to
conventional therapies (at a daily dose of
40 Y. Jiang et al. / Chronic Diseases and Translational Medicine 2 (2016) 34e413.6  1012 CFU/d), found that VSL#3 combination
therapy was safe, and more effective than conventional
therapy alone in achieving higher responses and
remission rates in mild to moderately active UC.
Kumar et al38 reported that when histopathological
changes were induced by trinitrobenzenesulfonic
acid, Lactobacillus attenuated the macroscopic
colonic damage. Furthermore, Lactobacillus signifi-
cantly decreased thiobarbituric acid reactive sub-
stances and nitric oxide production and increased
glutathione concentrations, as well as down-regulated
the expressions of interleukin-1b and tumor necrosis
factor-a, whereas protein and mRNA expression of
interleukin-10 were up-regulated. A randomized
clinical trial39 with children having active distal UC
was conducted and rectal infusion of Lactobacillus
reuteri was found to be effective in improving
mucosal inflammation and altering mucosal expres-
sion levels of some cytokines involved in the mech-
anisms of inflammatory bowel disease. Thus, there is
evidence that Lactobacillus may be a useful medica-
tion in the treatment of UC.
Probiotics appear to be well tolerated. No difference
in the incidence of adverse events was observed be-
tween probiotics and aminosalicylates. In a meta-
analysis of adverse events performed by Naidoo
et al,15 no statistically significant difference in the
incidence of side effects was observed between the
probiotic group and the mesalazine group on main-
taining the remission of UC. Serious adverse effects
from probiotics are rarely reported because they are
well tolerated and safe.40 These findings indicate that
probiotics are very safe in clinical usage.
Future studies on the value of probiotics for the
maintenance of remission in patients with UC should
consider the effects of different kinds of probiotics, as
different types of UC may benefit from probiotic use.
Several limitations exist in our meta-analysis.
Firstly, we cannot eliminate publication bias, despite
attempting to find both positive and negative results.
Second, only six trials satisfied the inclusion criteria
and were included in our study. Moreover, the number
of patients included in these studies is relatively small,
and thus they are not considered optimal-quality
studies. Third, there are limited reports of side effects
in the included studies (only three articles mentioned
any). Fourth, mixed probiotics, such as VSL#3, may be
more effective than singular probiotics; however, we
did not find any RCTs that compared mixed probiotics
with aminosalicylates. Lastly, the majority of the
studies we analyzed did not indicate the type of UC or
whether patients had multiple treatments. The initialtreatments of mild UC often show self-healing ten-
dencies, and therefore, it may be more significant to
compare the maintenance effect of medications in pa-
tients with moderate to severe UC.
In conclusion, probiotics, as well as amino-
salicylates, showed therapeutic effects on UC. How-
ever, the number of patients in the studies analyzed
was relatively small, the quality of the RCTs was
inadequate, and there was no information regarding
whether patients were receiving initial treatments or
multiple treatments. Thus, more well-designed RCTs
are required.
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